High gastrin releasing peptide receptor mRNA level is related to tumour dedifferentiation and lymphatic vessel invasion in human colon cancer

Saurin, Jean Christophe; Rouault, Jean‐Pierre; Abello, Jacques; Berger, F; Rémy, Lionel; Chayvialle, Jean‐Alain

doi:10.1016/s0959-8049(98)00276-7

Cited by 32 publications

(19 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While both normal hepatic cell line and the two human HCC cell lines expressed detectable GRP and GRPR protein and mRNA, much higher levels of GRP and GRPR were detected in HepG2 and MHCC97H cells than in HL77-02 cells. These results indicated that GRP and GRPR were coexpressed in the two human HCC cell lines, consistent with previous observations with other tumor cells (3)(4)(5)(6)(7). Such a general coexpression pattern may suggest important biological effects, thus prompting us to further observe the influence of GRP on the growth of HepG2 cells with elevated GRP and GRPR expressions.…”

Section: Discussionsupporting

confidence: 90%

“…The MAPK/ERK1/2 signaling pathway is a critically important signaling pathway promoting proliferation and migration of tumor cells, and activation of ERK1/2 in HepG2 cells might lead to the transcription of multiple genes required for growth and invasion (21,22). Thus, our results are consistent with an important role of GRP in the growth of liver cancer cells as observed in other tumor cells (1)(2)(3)(4)(5)(6)(7)(15)(16)(17)(18).…”

Section: Discussionsupporting

confidence: 89%

“…For example, extensive studies have shown that mammalian bombesin-like gastrin-releasing peptide (GRP) binds to its cognate receptor (GRPR) and exerts various biological effects in tumors (1,2). In particular, GRP serves as a potent mitogen for various types of tumor including small cell lung, pancreatic, prostate, renal, breast and colon cancers (1)(2)(3)(4)(5)(6)(7). Furthermore, treatment with GRP antibody was found to lead to significant anti-proliferative effects, indicating that GRP is an autocrine growth factor and GRPR may be a drug target for tumor imaging and anti-tumor therapy (8)(9)(10)(11)(12)(13)(14).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Gastrin-releasing peptide promotes the growth of HepG2 cells via EGFR-independent ERK1/2 activation

Lv²,

Yuan³

et al. 2010

Oncol Rep

View full text Add to dashboard Cite

Abstract. Gastrin-releasing peptide (GRP) plays an important role in regulating tumor growth and migration. However, little is known about its role in human hepatocellular carcinoma (HCC) cells. This study explored the effect of GRP on the growth of HCC HepG2 cells and the underlying mechanisms. Expression of GRP and its cognate receptor (GRPR) were detected by immunocytochemisty, reverse transcription-PCR and Western blotting and compared between two human HCC cell lines (HepG2 and MHCC97H) and a normal hepatic cell line (HL-7702). The effects of GRP on cell proliferation and signaling pathways were examined by Western blotting, MTT assay and flow cytometry. Both GRP and GRPR were overexpressed in HepG2 and MHCC97H cells. GRP activated MAPK/ERK1/2 in HepG2 cells, leading to enhanced proliferation, reduced apoptosis and accelerated cell cycle progression. The effect of GRP on ERK1/2 was effectively attenuated by the GRPR antagonist PD176252 or MEK inhibitor U0126, but not by the TNF-· protease inhibitor TAPI-1 or the EGFR tyrosine kinase inhibitor PD153035. The effect of GRP on the growth of HepG2 cells was significantly attenuated by PD176252 or U0126. GRP serves as a mitogen for HepG2 and MHCC97H cells. GRP promotes the growth of HepG2 cells through interaction with GRPR co-expressed in tumor cells, and subsequently activates MAPK/ERK1/2 via EGFRindependent mechanisms.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionsupporting

confidence: 89%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Gastrin-releasing peptide promotes the growth of HepG2 cells via EGFR-independent ERK1/2 activation

Lv²,

Yuan³

et al. 2010

Oncol Rep

View full text Add to dashboard Cite

show abstract

“…24 Studies have shown that receptors for GRP (GRP-Rs) are overexpressed in human CRC and human CRC cell lines when compared with normal colonic epithelial cells. [25][26][27][28][29][30][31] Review of all studies of GRP-R aberrantly expressed by human CRC and cell lines of CRC indicates that a higher proportion of tumors express receptor mRNA than express functional protein. 9,26,31 All three human CRC cell lines used in our study expressed mRNA as well as protein for GRP-R and NMB-R, while mRNA and protein for BRS-3 could only be detected by western blot and (p < 0.05) for the combination of RC-3940-II and irinotecan vs. single substances ( Table 1).…”

Section: Resultsmentioning

confidence: 99%

Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers

et al. 2012

View full text Add to dashboard Cite

“…GRPR is overexpressed in a wide variety of human malignancies, including prostate [14,15,16], breast [17,18,19], lung [17, 20], head and neck [21], gastric [22, 23], colon [24,25,26,27], esophageal [28] and renal cancer [29, 30]. Among gynecological tumors, GRPRs were detected in high density in ovarian [31] and uterine carcinomas [32].…”

Section: Introductionmentioning

confidence: 99%

Gastrin-Releasing Peptide Receptor Expression in Cervical Cancer

Cornélio

Meurer²,

Roesler

et al. 2007

Oncology

View full text Add to dashboard Cite

Objectives: It was the aim of this study to evaluate whether cervical neoplasms and adjacent tissues express the gastrin-releasing peptide receptor (GRPR) and whether there is a significant difference in its distribution among preinvasive and invasive cancers. Methods: Sections of paraffin-embedded cervical tumors (n = 88) and non-neoplastic control cervical tissues (n = 14) obtained from women registered in the Pathology Department, Academic Hospital, Federal University of Rio Grande do Sul, Porto Alegre, Brazil, were investigated by immunohistochemistry for GRPR. Results: GRPR was detected in 99% of tumor specimens, mostly exhibiting a diffuse strong staining. The receptors were seldom detected in the endocervices, while ectocervices expressed GRPRs only when adjacent to neoplastic lesions. No correlation between GRPR expression and preinvasive and invasive neoplasms was found. Conclusions: To the best of our knowledge, this is the first demonstration of the widespread GRPR expression in human cervical cancer. The presence of receptors both in tumors and surrounding tissues may suggest that GRPR can play a role in the cervical carcinogenic process. These data provide a molecular basis for exploiting GRPR as a target for diagnostic and therapeutic purposes in cervical neoplasms.

show abstract

High gastrin releasing peptide receptor mRNA level is related to tumour dedifferentiation and lymphatic vessel invasion in human colon cancer

Cited by 32 publications

References 22 publications

Gastrin-releasing peptide promotes the growth of HepG2 cells via EGFR-independent ERK1/2 activation

Gastrin-releasing peptide promotes the growth of HepG2 cells via EGFR-independent ERK1/2 activation

Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers

Gastrin-Releasing Peptide Receptor Expression in Cervical Cancer

Contact Info

Product

Resources

About